

P1156

## TWO YEAR FOLLOW UP QUALITY INDICATORS COMPLIANCE IN A LARGE INTERNATIONAL PERITONEAL DIALYSIS INSTITUTION

Belén Marrón<sup>1</sup>, Suzanne Pearce<sup>2</sup>, Claudia Martín<sup>3</sup>, Dan Munteanu<sup>4</sup>, Michael Roesch<sup>5</sup>, Janusz Ostrowski<sup>6</sup>, Marietta Torok<sup>7</sup>, Daniel Pérez<sup>8</sup>, Attila Orosz<sup>9</sup>, Pawel Kochman<sup>6</sup>, Charlotta Wollheim<sup>10</sup>, Carlos Lucas<sup>11</sup>, Fernando Macário<sup>12</sup>

<sup>1</sup>Diaverum Renal Services, Corporate Home Therapies & Patient Safety Director. Medical Office, Mälmo, Sweden, <sup>2</sup>Diaverum Renal Services, Corporate Nursing Director. Medical Office, Mälmo, Sweden, <sup>3</sup>Diaverum Renal Services, Barracas Clinic, Buenos Aires, Argentina, <sup>4</sup>Diaverum Renal Services, Fundeni Clinic, Bucharest, Romania, <sup>5</sup>Diaverum Renal Services, Schlankreye Clinic, Hamburgo, Germany, <sup>6</sup>Diaverum Renal Services, Wloclawek Clinic, Wloclawek, Poland, <sup>7</sup>Diaverum Renal Services, Corporate Medical Integration Director. Medical Office, Mälmo, Sweden, <sup>8</sup>Diaverum Renal Services, SEINE Clinic, Montevideo, Uruguay, <sup>9</sup>Diaverum Renal Services, Bajcsy Clinic, Budapest, Hungary, <sup>10</sup>Diaverum Renal Services, Corporate Data Management Director. Medical Office, Mälmo, Sweden, <sup>11</sup>Diaverum Renal Services, Corporate Medical Protocols & Standarization, Mälmo, Sweden and <sup>12</sup>Diaverum Renal Services, VP Medical Office, Mälmo, Sweden

Background and Aims: Peritoneal dialysis (PD) practice is not universally homogeneous, best clinical practices are not completely understood as reference values are often obtained from small sized populations and/or frequently based on chronic kidney disease (CKD) and/or hemodialysis data.

To evaluate two years of follow up of compliance with PD-related quality indicators (QIs) following definition of new targets in an international PD network.

**Method:** All English and Spanish language CKD and PD guidelines were reviewed. Twelve Qis were considered being of significant relevance and targets for these QIs were defined (see table). Retrospective data analysis.

**Results:** Achievement of QI targets for years 2017-2018 is shown in table. Variability among countries not shown.

Conclusion: There was a significant increase in QIs achievement in 2018 vs. 2017. ≥75% of patients met the target for the following variables: total weekly Kt/Vurea, 24 h fluid removal, mean arterial blood pressure and serum albumin. Peritonitis rates are clearly over International objectives and were improving. Due to the lack of referral source data, these series may help to understand PD practice and outcomes in a global setting.

2017 vs. 2018	2017	2018	
Total PD patients (pt., n)	1200	1207	
Total PD pt data on registry (n)	879	857	
Pt. by Regions (Eu/LA/Others)	532/339/8	508/342/7	
Age (y.)	53.8	54	
DM (%)	18.3	18,4	
Charlson index (Last quarter)	4.3	4.4	
CAPD use (Last quarter, %)	76.2	74.5	
Mean time on PD (months)	34,2	36.1	
Qls achievement (%)	2017	2018	p<0.001
Total weekly Kt/V ≥ 1.7	79.2	79.5	
(including anurics)			
24 h fluid removal [24 h residual diuresis	96.9	96.7	
+24 h ultrafiltration]: ≥750 ml/day			
(including anurics)			
Albumin ≥35 g/L	74.0	76.6	
nPNA ≥ 0.8 g/kg/day	68.6	68.0	
Serum K: 3.5-5.5 mEq/L	74.9	72.3	
Serum bicarbonate: 24-28 mEq/L	40.9	41.7	
Serum phosphorus: 2.5-5.5 mg/dl	65.5	63.5	
Serum calcium: 8.6-10 mg/dl	67.1	65.8	
Intact parathyroid hormone:	64,4	65.9	
100-600 pg/ml			
Hb: 10-12 g/dl (all patients)	58.0	58.8	
Serum ferritin: 100-500 ng/ml	50.6	51.1	
Mean arterial blood pressure	79.2	80.2	
< 105 mm Hg			
Total score	819.3	820.1	
Others			
Hb: 10-12 g/dl (ESA treated)	65.5	65	
Hb: >12 g/dl (non- ESA treated)	57.6	52,7	
Peritonitis rates	0.25	0,18	
(episodes/pt-year at risk)			